<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00246740</url>
  </required_header>
  <id_info>
    <org_study_id>Protect Study Protocol</org_study_id>
    <nct_id>NCT00246740</nct_id>
  </id_info>
  <brief_title>Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting</brief_title>
  <official_title>Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether doxycycline (Periostat) at a
      sub-antimicrobial dose will decrease reperfusion injury after coronary artery bypass grafting
      (CABG) surgery with cardiopulmonary bypass (CPB).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposal is for a randomized, placebo-controlled, double-blinded study of the use of
      doxycycline in patients requiring CABG surgery. Patients will be randomized 1:1 to receive
      either doxycycline or placebo.

      This study will be conducted in a blinded manner. The pharmacy will randomize patients and
      will have the randomization code. The code will only be broken in the case of an emergency
      and the event will be fully documented.

      In addition to standard care, patients will receive oral administration of 20 mg of
      doxycycline or placebo twice a day at least 2 days prior to surgery, on the day of surgery,
      and on postoperative days 1, 2, and 3.

      Myocardial atrial biopsies will be taken at 2 time points during the CABG procedure: during
      cannulation of the right atrium and 10 minutes after cross-clamp release. Tissue will be
      analyzed for MMP-2 and -9 activity and TnI and MLC-1 levels.

      A Swan-Ganz-Catheter will be placed in the pulmonary artery over 24 hours to measure
      hemodynamics (LVSWI).

      A coronary sinus catheter will be placed under echocardiographic guidance prior to initiation
      of CPB (will be removed 20 minutes after cross-clamp release).

      Patients will have an additional ECG on post-operative days 1 and 3.

      Additional blood will be drawn to determine doxycycline plasma levels, MMP-2 and -9 activity,
      total gelatinolytic activity, and levels of troponin I and T products at the following time
      points: pre-induction, prior to initiation of CPB, 10 and 20 minutes following the release of
      the aortic cross clamp (arterial and venous) and 3, 6, 24 and 72 hours post aortic cross
      clamp removal (venous). Each of the above samples will require 6 mL of blood for a study
      total of 72 mL. At the time of each blood draw we will measure and record the hematocrit
      value.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Stroke Work Index (LVSWI)</measure>
    <time_frame>Before surgery up to 24h of reperfusion</time_frame>
    <description>Measure of global left ventricular function. The formula used for calculation is: LVSWI= SI x MAP x 0.0144 LVSWI = Left Ventricular Stroke Work Index (g*m/m2) SI = Stroke Index (mL/beat/m2) MAP = Mean Arterial Pressure (mmHg) 0.0144 is a conversion term to equalize units.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Matrix Metalloproteinase-9 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion</measure>
    <time_frame>Before surgery and 10 minutes reperfusion after surgery</time_frame>
    <description>Biochemical activity of MMP-9 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery. To determine MMP-9 activity, 20 Î¼g of total protein from both myocardial extracts and plasma were analyzed by gelatin zymography. For detailed methodology consult Cheung PY, Sawicki G, Wozniak M, et al: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101:1833-1839</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Matrix Metalloproteinase-2 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion</measure>
    <time_frame>Before surgery and 10 minutes reperfusion after surgery</time_frame>
    <description>Biochemical activity of MMP-2 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Plasma Cardiac Matrix Metalloproteinase-9 Activity Before and After Reperfusion</measure>
    <time_frame>Before surgery and up to 72 h reperfusion after surgery</time_frame>
    <description>Biochemical activity of MMP-9 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Plasma Cardiac Matrix Metalloproteinase-2 Activity Before and After Reperfusion</measure>
    <time_frame>Before surgery and up to 72 h reperfusion after surgery</time_frame>
    <description>Biochemical activity of MMP-2 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Plasma Concentration of Troponin-I</measure>
    <time_frame>Before surgery and 10 minutes reperfusion after surgery</time_frame>
    <description>Measurement of levels of TnI (troponin-I), a marker of cardiac cell damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cleaved TroponinI/GAPDH Ratios in Right Atrial Biopsy</measure>
    <time_frame>Before surgery and 10 minutes reperfusion after surgery</time_frame>
    <description>Measurement of the ratios of cleaved TnI (troponin-I) versus GAPDH in biopsies collected from right atria. Measure is the ratio TnI/GAPDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Plasma Concentration of C-reactive Protein</measure>
    <time_frame>Before surgery and up to 72 h reperfusion after surgery</time_frame>
    <description>Measurement of inflammation marker C-reactive protein in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Plasma Concentration of IL-6</measure>
    <time_frame>Before surgery and up to 72 h reperfusion after surgery</time_frame>
    <description>Measurement of inflammation marker interleukin-6 in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Coronary Artery Bypass Grafting</condition>
  <condition>Cardiopulmonary Bypass</condition>
  <condition>Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Placebo oral tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Periostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Periostat</intervention_name>
    <description>In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
    <arm_group_label>Periostat</arm_group_label>
    <other_name>Doxycycline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
    <arm_group_label>Placebo oral tablet</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Aged 18 through 80 years, inclusive

          -  Scheduled for primary CABG surgery with CPB

        Exclusion Criteria:

          -  Females of childbearing potential

          -  Emergency CABG

          -  Previous sternotomy

          -  Planned simultaneous surgery (i.e. valve repair or carotid endarterectomy)

          -  Myocardial infarction within 48 hours

          -  Pre-operative atrial fibrillation

          -  Pre-operative ventricular pacing or left bundle branch block (LBBB)

          -  Known hypersensitivity to tetracycline class antibiotics

          -  Renal failure requiring dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry A Finegan, FFARCS FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology and Pain Medicine, University of Alberta Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://dx.doi.org/10.1097/CCM.0b013e318292373c</url>
    <description>DOI of published results paper</description>
  </link>
  <results_reference>
    <citation>Schulze CJ, Castro MM, Kandasamy AD, Cena J, Bryden C, Wang SH, Koshal A, Tsuyuki RT, Finegan BA, Schulz R. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass. Crit Care Med. 2013 Nov;41(11):2512-20. doi: 10.1097/CCM.0b013e318292373c.</citation>
    <PMID>23928836</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2005</study_first_submitted>
  <study_first_submitted_qc>October 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2005</study_first_posted>
  <results_first_submitted>January 16, 2017</results_first_submitted>
  <results_first_submitted_qc>May 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 15, 2017</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Barry Finegan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Doxycycline</keyword>
  <keyword>coronary artery bypass grafting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Oral Tablet</title>
          <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
        </group>
        <group group_id="P2">
          <title>Periostat</title>
          <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Enrollment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Additional surgery scheduled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery schedule change</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Experimental Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Oral Tablet</title>
          <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
        </group>
        <group group_id="B2">
          <title>Periostat</title>
          <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="1.5"/>
                    <measurement group_id="B2" value="63.1" spread="2"/>
                    <measurement group_id="B3" value="63.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Stroke Work Index (LVSWI)</title>
        <description>Measure of global left ventricular function. The formula used for calculation is: LVSWI= SI x MAP x 0.0144 LVSWI = Left Ventricular Stroke Work Index (g*m/m2) SI = Stroke Index (mL/beat/m2) MAP = Mean Arterial Pressure (mmHg) 0.0144 is a conversion term to equalize units.</description>
        <time_frame>Before surgery up to 24h of reperfusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Tablet</title>
            <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
          <group group_id="O2">
            <title>Periostat</title>
            <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Stroke Work Index (LVSWI)</title>
          <description>Measure of global left ventricular function. The formula used for calculation is: LVSWI= SI x MAP x 0.0144 LVSWI = Left Ventricular Stroke Work Index (g*m/m2) SI = Stroke Index (mL/beat/m2) MAP = Mean Arterial Pressure (mmHg) 0.0144 is a conversion term to equalize units.</description>
          <units>g*m/m2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" spread="2.6"/>
                    <measurement group_id="O2" value="43" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="1.7"/>
                    <measurement group_id="O2" value="28" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="1.8"/>
                    <measurement group_id="O2" value="29" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" spread="1.9"/>
                    <measurement group_id="O2" value="29" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" spread="1.4"/>
                    <measurement group_id="O2" value="25" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" spread="1.6"/>
                    <measurement group_id="O2" value="30" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="1.8"/>
                    <measurement group_id="O2" value="33" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Matrix Metalloproteinase-9 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion</title>
        <description>Biochemical activity of MMP-9 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery. To determine MMP-9 activity, 20 Î¼g of total protein from both myocardial extracts and plasma were analyzed by gelatin zymography. For detailed methodology consult Cheung PY, Sawicki G, Wozniak M, et al: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101:1833â1839</description>
        <time_frame>Before surgery and 10 minutes reperfusion after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Tablet</title>
            <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
          <group group_id="O2">
            <title>Periostat</title>
            <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Matrix Metalloproteinase-9 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion</title>
          <description>Biochemical activity of MMP-9 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery. To determine MMP-9 activity, 20 Î¼g of total protein from both myocardial extracts and plasma were analyzed by gelatin zymography. For detailed methodology consult Cheung PY, Sawicki G, Wozniak M, et al: Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101:1833â1839</description>
          <units>Arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".75" spread=".25"/>
                    <measurement group_id="O2" value="1.56" spread=".26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".44" spread=".28"/>
                    <measurement group_id="O2" value="1.63" spread=".29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Matrix Metalloproteinase-2 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion</title>
        <description>Biochemical activity of MMP-2 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery.</description>
        <time_frame>Before surgery and 10 minutes reperfusion after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Tablet</title>
            <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
          <group group_id="O2">
            <title>Periostat</title>
            <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Matrix Metalloproteinase-2 Activity in Right Atrial Biopsies at 10 Minutes Reperfusion</title>
          <description>Biochemical activity of MMP-2 activity in right atrial biopsies, measured at 10 minutes of reperfusion after surgery.</description>
          <units>Arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".36" spread=".04"/>
                    <measurement group_id="O2" value=".24" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".42" spread=".04"/>
                    <measurement group_id="O2" value=".25" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Plasma Cardiac Matrix Metalloproteinase-9 Activity Before and After Reperfusion</title>
        <description>Biochemical activity of MMP-9 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.</description>
        <time_frame>Before surgery and up to 72 h reperfusion after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Tablet</title>
            <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
          <group group_id="O2">
            <title>Periostat</title>
            <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Plasma Cardiac Matrix Metalloproteinase-9 Activity Before and After Reperfusion</title>
          <description>Biochemical activity of MMP-9 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.</description>
          <units>Arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".07" spread=".04"/>
                    <measurement group_id="O2" value=".11" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".06" spread=".04"/>
                    <measurement group_id="O2" value=".12" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread=".08"/>
                    <measurement group_id="O2" value="1.37" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread=".09"/>
                    <measurement group_id="O2" value="1.3" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".52" spread=".08"/>
                    <measurement group_id="O2" value=".53" spread=".08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".21" spread=".04"/>
                    <measurement group_id="O2" value=".22" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".05" spread=".03"/>
                    <measurement group_id="O2" value=".09" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".03" spread=".01"/>
                    <measurement group_id="O2" value=".03" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Plasma Cardiac Matrix Metalloproteinase-2 Activity Before and After Reperfusion</title>
        <description>Biochemical activity of MMP-2 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.</description>
        <time_frame>Before surgery and up to 72 h reperfusion after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Tablet</title>
            <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
          <group group_id="O2">
            <title>Periostat</title>
            <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Plasma Cardiac Matrix Metalloproteinase-2 Activity Before and After Reperfusion</title>
          <description>Biochemical activity of MMP-2 activity in venous plasma, measured before surgery and up to 72h of reperfusion after surgery.</description>
          <units>Arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".99" spread=".05"/>
                    <measurement group_id="O2" value="1.06" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".93" spread=".04"/>
                    <measurement group_id="O2" value=".96" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread=".06"/>
                    <measurement group_id="O2" value="1.05" spread=".06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".87" spread=".04"/>
                    <measurement group_id="O2" value="1" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".99" spread=".05"/>
                    <measurement group_id="O2" value="1.06" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".92" spread=".07"/>
                    <measurement group_id="O2" value="1.07" spread=".07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".78" spread=".05"/>
                    <measurement group_id="O2" value=".9" spread=".05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".78" spread=".04"/>
                    <measurement group_id="O2" value=".9" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Plasma Concentration of Troponin-I</title>
        <description>Measurement of levels of TnI (troponin-I), a marker of cardiac cell damage</description>
        <time_frame>Before surgery and 10 minutes reperfusion after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Tablet</title>
            <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
          <group group_id="O2">
            <title>Periostat</title>
            <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Plasma Concentration of Troponin-I</title>
          <description>Measurement of levels of TnI (troponin-I), a marker of cardiac cell damage</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread=".33"/>
                    <measurement group_id="O2" value="1.07" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread=".46"/>
                    <measurement group_id="O2" value="1.78" spread=".47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cleaved TroponinI/GAPDH Ratios in Right Atrial Biopsy</title>
        <description>Measurement of the ratios of cleaved TnI (troponin-I) versus GAPDH in biopsies collected from right atria. Measure is the ratio TnI/GAPDH</description>
        <time_frame>Before surgery and 10 minutes reperfusion after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Tablet</title>
            <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
          <group group_id="O2">
            <title>Periostat</title>
            <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Cleaved TroponinI/GAPDH Ratios in Right Atrial Biopsy</title>
          <description>Measurement of the ratios of cleaved TnI (troponin-I) versus GAPDH in biopsies collected from right atria. Measure is the ratio TnI/GAPDH</description>
          <units>Arbitrary units-Cleaved TnI/GAPDH</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1318" spread=".3852"/>
                    <measurement group_id="O2" value="2.3454" spread=".3978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5195" spread=".3745"/>
                    <measurement group_id="O2" value="2.1893" spread=".3868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Plasma Concentration of C-reactive Protein</title>
        <description>Measurement of inflammation marker C-reactive protein in plasma</description>
        <time_frame>Before surgery and up to 72 h reperfusion after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Tablet</title>
            <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
          <group group_id="O2">
            <title>Periostat</title>
            <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Plasma Concentration of C-reactive Protein</title>
          <description>Measurement of inflammation marker C-reactive protein in plasma</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="2"/>
                    <measurement group_id="O2" value="10" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="1.8"/>
                    <measurement group_id="O2" value="9.9" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1.3"/>
                    <measurement group_id="O2" value="7.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="1.5"/>
                    <measurement group_id="O2" value="7.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.7"/>
                    <measurement group_id="O2" value="9.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="2"/>
                    <measurement group_id="O2" value="16.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="1.9"/>
                    <measurement group_id="O2" value="48.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" spread="1.2"/>
                    <measurement group_id="O2" value="51.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Venous Plasma Concentration of IL-6</title>
        <description>Measurement of inflammation marker interleukin-6 in plasma</description>
        <time_frame>Before surgery and up to 72 h reperfusion after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Oral Tablet</title>
            <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
          <group group_id="O2">
            <title>Periostat</title>
            <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Venous Plasma Concentration of IL-6</title>
          <description>Measurement of inflammation marker interleukin-6 in plasma</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="2"/>
                    <measurement group_id="O2" value="1.9" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After anesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.9"/>
                    <measurement group_id="O2" value="2.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="2.7"/>
                    <measurement group_id="O2" value="7.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" spread="3.3"/>
                    <measurement group_id="O2" value="15.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" spread="6.6"/>
                    <measurement group_id="O2" value="76.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" spread="5.9"/>
                    <measurement group_id="O2" value="83.4" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="6.4"/>
                    <measurement group_id="O2" value="71.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 h reperfusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="5.7"/>
                    <measurement group_id="O2" value="28.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>72 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Oral Tablet</title>
          <description>Patients received oral administration of matching placebo pills, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Placebo Oral Tablet: In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
        </group>
        <group group_id="E2">
          <title>Periostat</title>
          <description>Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).
Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size. LVSWI does not estimate diastolic dysfunction. Right atrial biopsies may not reflect changes in left ventricular MMP activity. Doxycycline dose- and time-response analyses is required to better assess the protective effects</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Richard Schulz</name_or_title>
      <organization>Departments of Pediatrics and Pharmacology, University of Alberta</organization>
      <phone>780-492-6581</phone>
      <email>richard.schulz@ualberta.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

